Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polidocanol and sodium tetradecyl sulphate are sclerosing agents used in the treatment of varicose veins and telangiectasias. This specific entry refers to their use within the One Stop Vein Clinic (OSVeC) pilot study led by Imperial College London, which evaluates a same-day diagnosis and treatment model. Both agents function as detergents; when injected into a vein (often as a foam), they disrupt the lipid bilayer of endothelial cells, causing rapid cell death and exposing the subendothelial layers. This process triggers a localized thrombotic response that eventually leads to the replacement of the vein with a fibrous cord (sclerosis), effectively removing the varicose vein from circulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polidocanol + sodium tetradecyl sulphate (Imperial College London).